Su Chuan-Tsung, Wu Jih-Huah
Department of Healthcare Information and Management, Ming Chuan University, Taoyuan 33348, Taiwan.
Department of Biomedical Engineering, Ming Chuan University, Taoyuan 33348, Taiwan.
Life (Basel). 2022 Jun 9;12(6):862. doi: 10.3390/life12060862.
The 5-year survival rate of non-small-cell lung cancer (NSCLC) is still low (<21%) despite recent improvements. Since conventional therapies have a lot of side effects, combined therapy is strongly recommended. Here, we report a patient with advanced NSCLC who received combined therapy, including ceritinib, photobiomodulation (PBM), ACGL (Antrodia cinnamomea (A. cinnamomea), and Ganoderma lucidum (G. lucidum)). Based on combined therapy, suitable doses of A. cinnamomea, G. lucidum, and PBM are important for tumor inhibition. This case report presents clinical evidence on the efficacy of combined therapy in advanced NSCLC patients, including computed tomography (CT) scan, magnetic resonance imaging (MRI), carcinoembryonic antigen (CEA), and blood tests. The effective inhibition of human lung adenocarcinoma cells is demonstrated. Our case highlights important considerations for PBM and ACGL applications in NSCLC patients, the side effects of ceritinib, and long-term health maintenance.
尽管近期有所改善，但非小细胞肺癌（NSCLC）的5年生存率仍然很低（<21%）。由于传统疗法有很多副作用，强烈推荐联合治疗。在此，我们报告一名晚期NSCLC患者接受了包括色瑞替尼、光生物调节（PBM）、ACGL（樟芝和灵芝）在内的联合治疗。基于联合治疗，合适剂量的樟芝、灵芝和PBM对于肿瘤抑制很重要。本病例报告提供了联合治疗对晚期NSCLC患者疗效的临床证据，包括计算机断层扫描（CT）、磁共振成像（MRI）、癌胚抗原（CEA）和血液检查。证明了对人肺腺癌细胞的有效抑制。我们的病例突出了NSCLC患者中PBM和ACGL应用的重要考虑因素、色瑞替尼的副作用以及长期健康维持。
